Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Target Raised at Canaccord Genuity Group

Key Points

• Canaccord raised its Eton Pharmaceuticals price target from $68 to $80 and maintained a Buy rating, implying 39.49% upside from the previous close.
• Analyst sentiment is broadly positive: MarketBeat reports an average rating of Buy and a consensus price target of $77, with five analysts rating the stock Buy or Strong Buy and one Hold.
• Eton reported quarterly revenue of $57.93 million and EPS of $0.50, beating analyst estimates of $41.98 million and $0.31, respectively.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) had its price objective lifted by equities researchers at Canaccord Genuity Group from $68.00 to $80.00 in a research note issued on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's target price points to a potential upside of 39.49% from the stock's previous close.

Several other brokerages have also recently weighed in on ETON. Weiss Ratings raised Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research note on Tuesday, September 22nd. Craig Hallum reaffirmed a "buy" rating and issued a $78.00 price objective on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. B. Riley Financial reiterated a "buy" rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. HC Wainwright lifted their target price on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a "buy" rating in a report on Friday. Finally, Zacks Research raised Eton Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $77.00.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON traded up $10.20 during trading hours on Friday, reaching $57.35. The stock had a trading volume of 879,979 shares, compared to its average volume of 448,599. The stock has a market capitalization of $1.64 billion, a PE ratio of 151.17 and a beta of 0.89. Eton Pharmaceuticals has a 52 week low of $14.27 and a 52 week high of $66.37. The company has a 50 day moving average price of $54.92 and a two-hundred day moving average price of $36.26. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.31 by $0.19. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $57.93 million during the quarter, compared to analyst estimates of $41.98 million. As a group, sell-side analysts anticipate that Eton Pharmaceuticals will post 1.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the sale, the insider owned 37,025 shares in the company, valued at $2,409,216.75. This trade represents a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director owned 59,745 shares of the company's stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 79,166 shares of company stock valued at $4,809,672. 16.49% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth $68,629,000. Nantahala Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $42,569,426. Pillsbury Lake Capital LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $14,015,083. Panoramic Capital LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $7,537,000. Finally, Cannell Capital LLC purchased a new stake in Eton Pharmaceuticals in the second quarter worth about $6,181,041. Hedge funds and other institutional investors own 27.86% of the company's stock.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Record sales and earnings beat: Q3 product sales reached $57.9 million, up 158% year over year and above analyst expectations of about $42 million. Eton reported GAAP diluted EPS of $1.06 and non-GAAP diluted EPS of $0.50, both ahead of estimates. Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Raised 2026 guidance: Management now expects revenue above $175 million, up from its prior forecast of more than $145 million, and adjusted EBITDA above 40% of revenue, versus more than 35% previously. The company also said it exceeded its $200 million annualized revenue-run-rate goal five quarters ahead of schedule. Eton Pharma jumps after Q3 beat and guidance hike
• Positive Sentiment: Higher analyst target: HC Wainwright raised its price target from $70 to $80 and reiterated a Buy rating, signaling a more optimistic view of Eton’s prospects. HC Wainwright stock recommendations
• Neutral Sentiment: Pipeline update: Eton announced preliminary results from an ET-700 pilot study evaluating copper absorption inhibition and gastrointestinal tolerability; the headline did not provide enough detail to assess the findings’ potential impact. Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton's commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.